MYO10

Across TCGA pan-cancer cohorts, MYO10 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MYO10’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MYO10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MYO10 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where MYO10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.395	<.001	11	view →
CCRCC	All	III,IV	−0.478	<.001	9	view →
LSCC	Female	All	+0.248	.006	2	view →
LUAD	Male	All	−0.167	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MYO10–HNSC

Open the HNSC breakdown →